{"id":485,"date":"2021-07-20T12:00:00","date_gmt":"2021-07-20T12:00:00","guid":{"rendered":"https:\/\/nolato.wpengine.com\/mfn_news\/q2-2021-strong-increase-in-sales-and-profit\/"},"modified":"2021-07-20T12:00:00","modified_gmt":"2021-07-20T12:00:00","slug":"q2-2021-strong-increase-in-sales-and-profit","status":"publish","type":"mfn_news","link":"https:\/\/temporary.nolato.com\/fr\/mfn_news\/q2-2021-strong-increase-in-sales-and-profit\/","title":{"rendered":"Q2 2021: Strong increase in sales and profit"},"content":{"rendered":"
\n

\u2022 Sales increased to SEK 2,786 million (2,307)
\u2022 Operating profit (EBITA) rose to SEK\u00a0336 million (269), excl. a positive non-recurring item of SEK 50 million
\u2022 The EBITA margin amounted to 12.1% (11.7), excl. the non-recurring item
\u2022 Profit after tax increased to SEK 291 million (207)
\u2022 Diluted earnings per share increased to SEK 0.90 (0.78), excl. the non-recurring item
\u2022 Diluted earnings per share increased to SEK 1.08 (0.78)
\u2022 Cash flow after investments amounted to SEK 346 million (685)<\/p>\n

\u201cAll our business areas showed continued growth in the second quarter, resulting in the Group\u2019s net sales rising by 11%, adjusted for currency and acquisitions,\u201d said Christer Wahlquist, Nolato President and CEO. \u201cDespite some cost inflation and component shortages, our focus on efficiency and productivity has generated the desired effect and contributed to Nolato\u2019s highest ever profit for an individual quarter.\u201d<\/p>\n

Medical Solutions sales totaled SEK 1,021 million (700); adjusted for currency and acquisitions, sales grew by 2%. Operating profit (EBITA) rose by 24% to SEK 124 million (100) and the EBITA margin was 12.1% (14.3).<\/p>\n

\u201cThe EBITA margin has been impacted by a dilutive effect from the acquisition of GW Plastics in the third quarter of 2020,\u201d noted Christer Wahlquist. \u201cDemand has been good in most areas, but growth in diagnostics has been limited by available capacity. Volumes in the surgery area have continued to be adversely affected by postponed operations as a result of the pandemic, although demand increased quarter on quarter.\u201d<\/p>\n

\u201cThe planned expansion of production capacity in Switzerland, Hungary, Poland, the United States and Sweden is going according to plan.\u201d<\/p>\n

Integrated Solutions sales rose to SEK 1,186 million (1,149). Adjusted for currency, sales increased by 12%. Operating profit (EBITA) was SEK\u00a0154\u00a0million (166), with an EBITA margin of 13.0% (14.4).<\/p>\n

\u201cSales were fueled by continued strong growth in Vaporiser Heating Products (VHP) and solid performance in EMC,\u201d said Christer Wahlquist. \u201cIn line with our previous assessment, VHP volumes ramped up in the quarter, while EMC benefited from both the 5G roll-out and our initiatives within Automotive. We expect continued good sales growth for both VHP and EMC in the third quarter too compared with the second quarter of this year. However, there is a risk of disruptions due to temporary shortages of electronic components.\u201d<\/p>\n

Industrial Solutions sales totaled SEK 580 million (459); adjusted for currency and acquisitions, sales grew by a strong 22%. Operating profit (EBITA) rose sharply to SEK 62 million (11) and the EBITA margin was 10.7% (2.4).<\/p>\n

\u201cLast year, demand from the automotive industry was significantly impacted by our customers halting production for periods of the second quarter. The second quarter of this year was also adversely affected by supply chain disruptions, with component shortages causing some customers to halt operations or reduce production capacity for short periods,\u201d said Christer Wahlquist. \u201cThe efficiency improvements that have been undertaken, however, had a positive effect on profit and margins.\u201d<\/p>\n

Overall, consolidated group sales for the first six months of 2021 totaled SEK 5,431 million (4,372), which, adjusted for currency and acquisitions, is a strong increase of 15%. Operating profit (EBITA) rose to SEK 644 million (510), excluding non-recurring items, and diluted earnings per share were SEK 1.74 (1.49). Cash flow after investments was SEK 417 million (612) and the financial position remains strong.<\/p>\n<\/div>\n

\n

Contact<\/strong><\/p>\n\n

For further information, please contact:
Christer Wahlquist, President and CEO, +46 (0)705 804848
Per-Ola Holmstr\u00f6m, CFO, +46 (0)705 763340, per-ola.holmstrom@nolato.com<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n\n

Nolato is a Swedish group with operations in Europe, Asia, and North America. We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors. Nolato\u2019s shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector. \u00a0<\/em>www.nolato.com\/IR<\/a><\/em><\/p>\n<\/div>\n

\n

This information is information that Nolato is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-07-20 14:00 CEST.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n\n

Nolato Q2 2021 Interim Rep Eng<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2022 Sales increased to SEK 2,786 million (2,307)\u2022 Operating profit (EBITA) rose to SEK\u00a0336 million (269), excl. a positive non-recurring item of SEK 50 million\u2022 The EBITA margin amounted to 12.1% (11.7), excl. the non-recurring item\u2022 Profit after tax increased to SEK 291 million (207)\u2022 Diluted earnings per share increased to SEK 0.90 (0.78), excl.… Continue reading Q2 2021: Strong increase in sales and profit<\/span><\/a><\/p>\n","protected":false},"template":"","class_list":["post-485","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-report-interim-q2","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-report","mfn-news-tag-mfn-regulatory-vpml","entry"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"fr","enabled_languages":["en","es","de","fr","ru","sv"],"languages":{"en":{"title":true,"content":true,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"sv":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/mfn_news\/485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/media?parent=485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}